The Study On Compare And Prognostic In ET Patients With CALR And JAK2 Gene Mutation

ObjectiveBy studying the gene mutations of JAK2 and CALR in patients with essential thrombocytosis(ET),comparing the data which included Basic information(sex,age),Medical history(The history of bleeding,the history of thrombosis,the risk of CVR),Physical signs(Splenomegaly,Hepatomegaly),Peripheral blood routine(white blood cell,platelet,hemoglobin,D-Dimer),to investigate correlation between gene mutation of essential thrombocytosis and clinical information above.and assessing prognosis of groups of essential thrombocytosis patients which grouping by gene mutations.MethodScreening of ET patients which first visit outpatient and inpatient departments of our hospital from September 1st 2015 to September 1st 2017.A total of 37 patients were divided into JAK2 V617 F mutation group and CALR mutation group.The patients' sex,age,history of bleeding,history of thrombosis,CVR risk factors,abdominal color Doppler ultrasound and peripheral blood routine data were collected.To compare the above basic information,background data and some indexes of peripheral blood among different gene mutation groups.Based on the above data and the literature,analysing the pathogenesis of gene mutations and the prognosis of essential thrombocytosis.Result1.A total of 24 cases of JAK2 V617 F gene mutation positive were detected in 37 cases of essential thrombocytosis,the positive expression rate is 64.9%;13 cases of CALR gene mutation positive were detected in 37 cases of essential thrombocytosis,the positive expression rate is 35.1%;no other gene mutation was detected.2.The incidence of thrombotic events in JAK2 V617 F mutation group was higher than in CALR mutation group,and statistical significance has be verified(P=0.013<0.05).3.The white blood cell count in JAK2 V617 F mutation group was higher than that in CALR mutation group,and statistical significance has be verified(P=0.009<0.05).4.The data which included sex,age,history of bleeding,CVR risk,splenomegaly,hepatomegaly,platelet,hemoglobin and D-Dimer were not statistically different between JAK2 V617 F and CALR mutation group(P<0.05).Conclusion1.In this study,the ratio of JAK2 V617 F mutation and CALR mutation in ET patients is approximately the same as that in domestic and foreign research.2.As for the white blood cell count and incidence of thrombotic events,the ET patients which with JAK2 V617 F gene mutation present higher value,compare to which one with CALR gene mutation.3.ET patients with JAK2 V617 F mutation had worse survival prognosis and higher thrombotic risk than ET patients with CALR mutation.